多种肿瘤标志物联合检测在胰腺癌诊治中的应用

Application of combined measurement of multiple serum tumor markers in diagnosis and treatment of pancreatic adenocarcinomas.

目的 探讨多种血清肿瘤标志物联合检测在胰腺癌诊治中的应用价值。方法 采用荧光免疫分析法和放射免疫法检测胰腺癌病人的血清CA5 0、CA19 9、CA12 5和CA2 42的表达 ,重点动态观察胰腺癌诊治过程中肿瘤标志物的表达及其临床随访价值。结果 CA19 9、CA2 42、CA5 0和CA12 5平行联合检测可提高胰腺癌诊断的敏感性 (90 2 % ) ,系列联合检测可提高其特异性 (93 5 % ) ;结合电子束断层摄影 (EBCT)检查 ,更可增加胰腺癌诊断的敏感性 (98 6 % )和特异性 (94 6 % )。动态监测术后多种肿瘤标志物有助于肿瘤复发和转移的随访。结论 动态联合检测CA19 9、CA2 42、CA5 0和CA12 5结合EBCT检查 。

Objective To study the value of combined measurement of multiple serum tumor markers in diagnosis and treatment of pancreatic carcinoma patients.Methods Four serum tumor markers including CA50,CA19-9,CA125 and CA242 were detected in pancreatic carcinoma patients by auto time-resolved fluorometric assay (ATRFMA)and immunoradiometric assay(IRMA).The application value of their dynamic observation,especially in association with electron beam computed tomography(EBCT)was studied.Results CA19-9,CA242,CA50 and CA125 were more valuable markers in the diagnosis of pancreatic carcinoma.The method of parallel testing could increase diagnostic sensitivity(90^2%),and series testing increased specificity(93^5%).Combining tumor markers and EBCT examination could increase diagnostic sensitivity(98^6%)and specificity(94^6%)even higher.It was useful for patients to be followed up by dynamically multiple tumor markers testing.Conclusion Serum CA19-9,CA242,CA50 and CA125 are valuable tumor markers in diagnosis and follow-up of pancreatic carcinoma;combining with EBCT can increase diagnostic sensitivity and specificity.